Gynecologic cancer intergroup (GCIG) consensus review for clear cell carcinoma of the uterine corpus and cervix

International Journal of Gynecological Cancer

Volumn 24, Issue 9, 2014, Pages S90-S95

  Hasegawa, Kosei ^a   Nagao, Shoji ^b   Yasuda, Masanori ^a   Millan, David ^d   Viswanathan, Akila N ^c   Glasspool, Rosalind M ^e   Devouassoux Shisheboran, Mojgan ^f   Covens, Alan ^g   Lorusso, Domenica ^h   Kurzeder, Christian ⁱ   Kim, Jae Weon ^j   Gladieff, Laurence ^k   Bryce, Jane ^l   Friedlander, Michael ^m   Fujiwara, Keiichi ^a  

^a SAITAMA MEDICAL UNIVERSITY   (Japan)

^b HYOGO CANCER CENTER   (Japan)

^c HARVARD MEDICAL SCHOOL   (United States)

^d SOUTHERN GENERAL HOSPITAL   (United Kingdom)

^e BEATSON WEST OF SCOTLAND CANCER CENTRE   (United Kingdom)

^f HOSPICES CIVILS DE LYON   (France)

^g DEPARTMENT OF RADIATION ONCOLOGY   (Canada)

^h NATIONAL CANCER INSTITUTE   (Italy)

ⁱ KLINIKEN ESSEN MITTE   (Germany)

^j Seoul National University College of Medicine   (South Korea)

^k INSTITUT CLAUDIUS REGAUD   (France)

^l NATIONAL CANCER INSTITUTE   (Italy)

^m PRINCE OF WALES HOSPITAL   (Australia)

more..

Author keywords

Clear cell carcinoma; Histological feature; Immunohistochemical; Treatment; Uterine cervix; Uterine corpus

Indexed keywords

CANCER ADJUVANT THERAPY; CANCER DIAGNOSIS; CANCER EPIDEMIOLOGY; CANCER RECURRENCE; CANCER STAGING; CANCER SURGERY; CLEAR CELL CARCINOMA; CYTOREDUCTIVE SURGERY; FEMALE; GENE MUTATION; GENOMIC INSTABILITY; HUMAN; IMMUNOHISTOCHEMISTRY; LYMPH NODE DISSECTION; METASTASIS; OMENTECTOMY; PRIORITY JOURNAL; REVIEW; SALPINGOOOPHORECTOMY; UTERINE CERVIX CARCINOMA; UTERINE CERVIX CYTOLOGY; UTERUS CARCINOMA; ADENOCARCINOMA, CLEAR CELL; CONSENSUS; MEDICAL SOCIETY; MULTIMODALITY CANCER THERAPY; ONCOLOGY; OVARIAN NEOPLASMS; PATHOLOGY; PRACTICE GUIDELINE; UTERINE NEOPLASMS;

ADENOCARCINOMA, CLEAR CELL; COMBINED MODALITY THERAPY; CONSENSUS; FEMALE; HUMANS; MEDICAL ONCOLOGY; OVARIAN NEOPLASMS; PRACTICE GUIDELINES AS TOPIC; SOCIETIES, MEDICAL; UTERINE NEOPLASMS;

EID: 84936108299     PISSN: 1048891X     EISSN: 15251438     Source Type: Journal    
DOI: 10.1097/IGC.0000000000000297     Document Type: Review

References (48)

1. Rauh-Hain JA, Davis M, Clemmer J, et al. Prognostic determinants in patients with uterine and ovarian clear cell carcinoma: A SEER analysis. Gynecol Oncol. 2013;131:404-409.
2. Olawaiye AB, Boruta DM II. Management of women with clear cell endometrial cancer: A Society of Gynecologic Oncology (SGO) review. Gynecol Oncol. 2009;113:277-283.
3. Mendivil A, Schuler KM, Gehrig PA. Non-endometrioid adenocarcinoma of the uterine corpus: A review of selected histological subtypes. Cancer Control. 2009;16:46-52.
4. Fadare O, Desouki MM, Gwin K, et al. Frequent expression of napsin A in clear cell carcinoma of the endometrium: potential diagnostic utility. Am J Surg Pathol. 2014;38:189-196.
5. Christopherson WM, Alberhasky RC, Connelly PJ. Carcinoma of the endometrium: I. A clinicopathologic study of clear-cell carcinoma and secretory carcinoma. Cancer. 1982;49:1511-1523.
6. Verloop J, van Leeuwen FE, Helmerhorst TJ, et al. Cancer risk in DES daughters. Cancer Causes Control. 2010;21:999-1007.
7. Lee L, Garrett L, Lee H, et al. Association of clear cell carcinoma of the endometrium with a high rate of venous thromboembolism. J Reprod Med. 2009;54:133-138.
8. Savvari P, Peitsidis P, Alevizaki M, et al. Paraneoplastic humorally mediated hypercalcemia induced by parathyroid hormone-related protein in gynecologic malignancies: A systematic review. Onkologie. 2009;32:517-523.
9. Thomas M, Mariani A, Wright JD, et al. Surgical management and adjuvant therapy for patients with uterine clear cell carcinoma: A multi-institutional review. Gynecol Oncol. 2008;108:293-297.
10. Abeler VM, Vergote IB, Kjorstad KE, et al. Clear cell carcinoma of the endometrium. Prognosis and metastatic pattern. Cancer. 1996;78:1740-1747.
11. Scully RE, Barlow JF. "Mesonephroma" of ovary. Tumor of Mullerian nature related to the endometrioid carcinoma. Cancer. 1967;20:1405-1417.
12. Ito H, Hirasawa T, Yasuda M, et al. Excessive formation of basement membrane substance in clear-cell carcinoma of the ovary: diagnostic value of the "raspberry body" in ascites cytology. Diagn Cytopathol. 1997;16:500-504.
13. Craighead PS, Sait K, Stuart GC, et al. Management of aggressive histologic variants of endometrial carcinoma at the Tom Baker Cancer Centre between 1984 and 1994. Gynecol Oncol. 2000;77:248-253.
14. Cirisano FD Jr, Robboy SJ, Dodge RK, et al. Epidemiologic and surgicopathologic findings of papillary serous and clear cell endometrial cancers when compared to endometrioid carcinoma. Gynecol Oncol. 1999;74:385-394.
15. Cirisano FD Jr, Robboy SJ, Dodge RK, et al. The outcome of stage IYII clinically and surgically staged papillary serous and clear cell endometrial cancers when compared with endometrioid carcinoma. Gynecol Oncol. 2000;77:55-65.
16. Hamilton CA, Cheung MK, Osann K, et al. Uterine papillary serous and clear cell carcinomas predict for poorer survival compared to grade 3 endometrioid corpus cancers. Br J Cancer. 2006;94:642-646.
17. Fadare O, Zheng W. Endometrial glandular dysplasia (EmGD): morphologically and biologically distinctive putative precursor lesions of type II endometrial cancers. Diagn Pathol. 2008;3:6.
18. Lax SF, Pizer ES, Ronnett BM, et al. Clear cell carcinoma of the endometrium is characterized by a distinctive profile of p53, Ki-67, estrogen, and progesterone receptor expression. Hum Pathol. 1998;29:551-558.
19. Chiang S, Soslow RA. Updates in diagnostic immunohistochemistry in endometrial carcinoma. Semin Diagn Pathol. 2014;31:205-215.
20. Yamamoto S, Tsuda H, Aida S, et al. Immunohistochemical detection of hepatocyte nuclear factor 1beta in ovarian and endometrial clear-cell adenocarcinomas and nonneoplastic endometrium. Hum Pathol. 2007;38:1074-1080.
21. Lax SF, Pizer ES, Ronnett BM, et al. Comparison of estrogen and progesterone receptor, Ki-67, and p53 immunoreactivity in uterine endometrioid carcinoma and endometrioid carcinoma with squamous, mucinous, secretory, and ciliated cell differentiation. Hum Pathol. 1998;29:924-931.
22. Arai T, Watanabe J, Kawaguchi M, et al. Clear cell adenocarcinoma of the endometrium is a biologically distinct entity from endometrioid adenocarcinoma. Int J Gynecol Cancer. 2006;16:391-395.
23. Lax SF. Molecular genetic pathways in various types of endometrial carcinoma: from a phenotypical to a molecular-based classification. Virchows Arch. 2004;444:213-223.
24. Zorn KK, Bonome T, Gangi L, et al. Gene expression profiles of serous, endometrioid, and clear cell subtypes of ovarian and endometrial cancer. Clin Cancer Res. 2005;11:6422-6430.
25. Cancer Genome Atlas Research N, Kandoth C, Schultz N, et al. Integrated genomic characterization of endometrial carcinoma. Nature. 2013;497:67-73.
26. Coosemans A, Moerman P, Verbist G, et al. Wilms' tumor gene 1 (WT1) in endometrial carcinoma. Gynecol Oncol. 2008;111:502-508.
27. Neoplasms NU. NCCN clinical practice guidelines in oncology uterine neoplasms. 2014.
28. Randall ME, Filiaci VL, Muss H, et al. Randomized phase III trial of whole-Abdominal irradiation versus doxorubicin and cisplatin chemotherapy in advanced endometrial carcinoma: A Gynecologic Oncology Group Study. J Clin Oncol. 2006;24:36-44.
29. Hogberg T, Signorelli M, de Oliveira CF, et al. Sequential adjuvant chemotherapy and radiotherapy in endometrial cancer-results from two randomised studies. Eur J Cancer. 2010;46:2422-2431.
30. Murphy KT, Rotmensch J, Yamada SD, et al. Outcome and patterns of failure in pathologic stages I-IV clear-cell carcinoma of the endometrium: implications for adjuvant radiation therapy. Int J Radiat Oncol Biol Phys. 2003;55:1272-1276.
31. Fleming GF, Brunetto VL, Cella D, et al. Phase III trial of doxorubicin plus cisplatin with or without paclitaxel plus filgrastim in advanced endometrial carcinoma: A Gynecologic Oncology Group Study. J Clin Oncol. 2004;22:2159-2166.
32. Miller D, Filiaci VL, Fleming GF, et al. Randomized phase III noninferiority trial of first line chemotherapy for metastatic or recurrent endometrial carcinoma: A Gynecologic Oncology Group study. Gynecol Oncol. 2012;125:771.
33. Khalifa MA, Mannel RS, Haraway SD, et al. Expression of EGFR, HER-2/neu, P53, and PCNA in endometrioid, serous papillary, and clear cell endometrial adenocarcinomas. Gynecol Oncol. 1994;53:84-92.
34. McMeekin DS, Filiaci VL, Thigpen JT, et al. The relationship between histology and outcome in advanced and recurrent endometrial cancer patients participating in first-line chemotherapy trials: A Gynecologic Oncology Group study. Gynecol Oncol. 2007;106:16-22.
35. Slomovitz BM, Lu KH, Johnston T, et al. A phase 2 study of the oral mammalian target of rapamycin inhibitor, everolimus, in patients with recurrent endometrial carcinoma. Cancer. 2010;116:5415-5419.
36. Rolitsky CD, Theil KS, McGaughy VR, et al. HER-2/neu amplification and overexpression in endometrial carcinoma. Int J Gynecol Pathol. 1999;18:138-143.
37. Tredan O, Treilleux I, Wang Q, et al. Predicting everolimus treatment efficacy in patients with advanced endometrial carcinoma: A GINECO group study. Target Oncol. 2012.
38. Kamat AA, Merritt WM, Coffey D, et al. Clinical and biological significance of vascular endothelial growth factor in endometrial cancer. Clin Cancer Res. 2007;13:7487-7495.
39. Herbst AL, Ulfelder H, Poskanzer DC. Adenocarcinoma of the vagina. Association of maternal stilbestrol therapy with tumor appearance in young women. N Engl J Med. 1971;284:878-881.
40. Hanselaar A, van Loosbroek M, Schuurbiers O, et al. Clear cell adenocarcinoma of the vagina and cervix. An update of the central Netherlands registry showing twin age incidence peaks. Cancer. 1997;79:2229-2236.
41. Thomas MB, Wright JD, Leiser AL, et al. Clear cell carcinoma of the cervix: A multi-institutional review in the post-DES era. Gynecol Oncol. 2008;109:335-339.
42. Seki H, Takada T, Sodemoto T, et al. Ayoung woman with clear cell adenocarcinoma of the uterine cervix. Int J Clin Oncol. 2003;8:399-404.
43. Wibur DC, Colgan TJ, Ferenczy AS, et al. Glandular tumours and precursors. In: Kurman RJ, Carcangiu ML, Herrington S, et al,, eds. WHO Classification of Tumours of Female Reproductive Organs. IARC; 2014: 183-194.
44. Pirog EC, Lloveras B, Molijn A, et al. HPV prevalence and genotypes in different histological subtypes of cervical adenocarcinoma, a worldwide analysis of 760 cases. Mod Pathol. 2014.
45. Boyd J, Takahashi H, Waggoner SE, et al. Molecular genetic analysis of clear cell adenocarcinomas of the vagina and cervix associated and unassociated with diethylstilbestrol exposure in utero. Cancer. 1996;77:507-513.
46. Hiromura T, Tanaka YO, Nishioka T, et al. Clear cell adenocarcinoma of the uterine cervix arising from a background of cervical endometriosis. Br J Radiol. 2009;82:e20-e22.
47. Ansari DO, Horowitz IR, Katzenstein HM, et al. Successful treatment of an adolescent with locally advanced cervicovaginal clear cell adenocarcinoma using definitive chemotherapy and radiotherapy. J Pediatr Hematol Oncol. 2012;34:e174-e176.
48. Chan KK, Ip P, Kwong P, et al. A combination of chemoirradiation and chemotherapy for treatment of advanced clear cell adenocarcinoma of the cervix. Int J Gynecol Cancer. 2008;18:559-563.